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Abstract 
Background: Tumor lysis syndrome (TLS) which mostly occurs in 
lymphoproliferative malignancies after the start of chemotherapy is an oncologic 
emergency. Manifestations of metabolic imbalance including increasing 
hyperkalemia, hyperphosphatemia, hyperuricemia and hypocalcemia are common 
presentation of TLS. 
Case report: We present two cases of spontaneous TLS; a rare presentation of TLS 
before cytotoxic chemotherapy. These cases were admitted with presentation of 
TLS without any history of chemotherapy with mediastinal mass in chest X-ray 
(CXR) and subsequent diagnosis of lymphoblastic lymphoma and T-cell acute 
lymphocytic leukemia (ALL). After several hemodialysis sessions, their conditions 
were improved and they underwent chemotherapy.  
Conclusions: It was found that the presentation of mediastinal mass in cases of 
lymphoma and acute leukemia might be associated with TLS before chemotherapy. 
In addition, it is important to pay attention to CXR, when we face to a patient with 
acute renal failure related to TLS. 
Key Words: Childhood Neoplasms, Leukemia, Lymphoma, Tumor Lysis 
Syndrome 
 
 
 
 
 
Introduction 
Tumor lysis syndrome (TLS) as a metabolic disorder includes oliguric renal 
failure (ORF), hyperuricemia, hyperphosphatemia and hyperkalemia and 
commonly occurs after the malignant cells are rapidly destructed, 
[1]
 leading to the 
release of uric acid, potassium, proteins, phosphate and other purine metabolites 
into the systemic circulation. The mentioned factors make excessive demands on 
the body’s homeostatic mechanisms and overcome the capacity of the renal system 
to excrete normally these materials. As the renal clearance of these chemical 
substances is overcome, the secondary hypocalcemia, hyperkalemia, hyperphosphatemia 
and hyperuricemia will occur and at the same time, the serum lactate dehydrogenase 
(LDH) level is often enhanced, too 
[2]
. Uncontrolled TLS results in acute renal 
failure (ARF) and lactic acidosis, clinically, leading to multi-organ defects 
including cardiac arrhythmias, acute kidney injury (AKI) as well as seizures or 
sudden death which needs intensive care. TLS is the most common oncologic 
emergency, and the mortality and morbidity increase without early diagnosis and 
prompt therapeutic intervention
 [3]
. TLS is less common in solid tumors and more 
common in high-grade leukemia and lymphoma with high white blood counts. During 
taking chemotherapy and cytotoxic drugs, often, this syndrome is iatrogenic 
[1]
. Few but 
remarkable case reports suggest that the TLS can happen in alternative conditions 
including the use of comparatively weak tumoricidal agents like glucocorticoids, 
treatment with radiation and administration of monoclonal therapy in addition to
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traditional cytotoxic agents 
[4-6]
. Spontaneous TLS 
which is much less common often occurs before 
cytotoxic therapy 
[7]
. In recent decades, the incidence of 
TLS has declined due to the physicians' attention and 
knowledge of the existence of this syndrome using 
appropriate prophylaxis before the start of 
chemotherapy. 
In the current study, we report two cases of renal 
failure related to TLS before diagnosis of 
malignancies, referred to hematology ward in Amirkola 
Children Hospital of Babol University of Medical 
Science. 
 
 
Case Presentations 
 
Case 1: 
A 12-year-old boy with lethargy, diarrhea and 
vomiting from previous day was referred to Amirkola 
Children's Hospital. He had normal growth and 
development and no history of hospitalization. He was 
ill, pale and dehydrated on examination. Abdominal 
exam was normal and without organomegaly. 
Petechiae, ecchymosis and purpura were observed on 
his both legs. 
Vital sign (VS): Blood Pressure (BP): 100/60 mm-
Hg, Pulse Rate (PR): 110/min, Respiratory Rate (RR): 
19/min and Body Temperature: 38.5˚ C.  
There was nothing abnormal on auscultation of the 
heart and lung sounds as well as the patient was 
nonoliguric. 
 
Laboratory data: 
White Blood Cell (WBC): 7500/dL), Hemoglobin 
(Hb): 7.7 (g/dL), Platelet (plt): 12000/dL). 
Venous Blood gases (VBG) PH: 7.11, PCO2: 31.5, 
HCO3: 10.2 
BUN: 135 (mg/dL), Creatinine (Cr): 3.2 (mg/dL), 
Sodium (Na): 130 (mg/dL), Potassium (K): 4.6 
(mg/dL), Calcium (Ca): 4.5 (mg/dL), Phosphorus (P): 
13.1 (mg/dL), Uric acid: 30 (mg/dL), LDH: 4095 (U/L)  
Coagulation and liver function tests and urine 
analysis (U/A) were in normal range. 
 
Patient with primary diagnosis of ARF as a result of 
HUS underwent on the basis of data laboratory 4 times 
hemodialysis and after that, his renal function was 
improved and creatinine level decreased from 3.2 mg/d) 
to 0.9 mg/dL over 10 days. There was no finding in 
abdominal sonography except mild hydronephrosis in 
both kidneys. CXR indicated a 3-4 centimetere 
diameter mass in right hilar and paracardiac regions. 
The CT scan revealed 28-38-mm diameter mass with a 
clear border at the anterolateral of superior vena cava 
(SVC)-right atrium, which could be invasive thymoma 
or mediastinal mass. Finally, during the core needle 
biopsy of mediastinal mass with the guide of 
ultrasound sonography, the lymphoma was diagnosed 
and immune histochemistry staining reported 
lymphoblastic lymphoma. Then, after hydration, the 
serum alkalization and oral administration of 
allopurinol chemotherapy started following the initial 
hemodialysis sessions. The patient’s condition was 
improved and no major complications were reported, 
thereafter. 
 
Case 2: 
The patient was an 11-year-old girl with severe 
respiratory distress from 2 days ago. She had the 
history of admission 2 months ago with renal failure 
post gastroenteritis with diagnosis of HUS and she 
underwent hemodialysis for five times and her 
creatinine level decreased from 5.7 mg/dL to 0.8 
mg/dL during 12 days. Next, she was discharged with 
good general condition and normal kidney function test 
and normal kidneys by abdominal ultrasonography. 
At the time of second admission, she was ill with 
intercostal and suprasternal retraction, wheezing on 
lung auscultation and jugular venous were prominent 
and her face seemed plethoric. CXR showed a large 
mass that occupied two-thirds of thoracic cage. 
Therefore, the SVC syndrome as an emergency case 
suggested the probability of lymphoma or leukemia. 
When we assessed her last CXR in previous 
admission (2 months ago), she had small mediastinal 
mass at that time. 
VS: BP: 105/60 mm-Hg, PR: 108/min, RR: 43/min 
and body Temperature: 37˚C 
 
Laboratory data: 
WBC: 9500/dL, Hb: 13.5 (g/dL), Plt: 372000/dL 
VBG: PH: 7.27, PCO2: 38.9, HCO3: 17.6 
BUN: 58 (mg/dL), Cr: 5.7 (mg/dL), Na: 129 
(mEq/L), K: 4.9 (mEq/L), Ca: 7.2 (mg/dL) 
P: 6.8 (mg/dL), Uric acide: 9.3 (mg/dL), LDH: 953 
(U/L) 
U/A: WBC: 2-4, RBC: many, SG: 1006 
Coagulation and liver function tests were in normal 
range. 
Bone marrow aspiration operation and immune 
phenotype by flow cytometry suggested the diagnosis 
of T-cell acute lymphocytic leukemia (ALL). The 
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patient underwent on chemotherapy, per protocol, with 
no further TLS related complications. Over subsequent 
weeks, the tumor mass shrank dramatically and the 
patient had good general condition. 
 
 
Discussion 
Both patients in this study presented with 
hyperuricemia, hyperphosphatemia and renal failure 
before diagnosis and starting chemotherapy named 
spontaneous TLS. Unlike the normal feature of TLS 
and in disagreement with Enomoto et al.'s study 
[7]
, our 
patients were not oliguric or hyperkalemic. 
Moreover, the hyperphosphatemia is less 
commonly observed with spontaneous TLS since the 
phosphate released in the spontaneous setting is 
deemed to be reapplied in the generation of new 
neoplastic cells which are less likely to assimilate with 
chemotherapy administration 
[8]
. 
Our findings were based on Cairo and Bishop 
modified criteria of TLS, commonly used as 
classification system. This system is represented in 
table 1 
[2, 9]
.  
It is assumed that the metabolic derangement would 
less often take place with spontaneous TLS due to the 
hypocalcemia resulting from serum calcium binding to 
excess phosphate 
[10]
. Unlike study of Kjellstrand 
CM.et al 
[8]
, our cases had hyperphosphatemia and 
hypercalcemia. Moreover, the presence of mediastinal 
mass is a considerable finding emphasizing that the 
chest X-ray (CXR) should be exactly seen in 
spontaneous TLS. 
A natural product of purine catabolism is 
considered as uric acid. Massive TLS, either in the 
context of cytotoxic therapy or spontaneous, can lead 
to acute hyperuricemia, causing a risk for renal failure 
(RF) secondary to uric acid nephropathy in patients 
[11]
. 
Both patients of the current study suffered from ARF. 
Today, it is believed that uric acid causes renal injury 
through inflammation and endothelial dysfunction 
though it is traditionally defined as an obstructive 
nephropathy because of intrarenal uric acid crystal 
deposition 
[11]
. 
Through initial diagnosis of RF, two patients of the 
present study were firstly undergone hemodialysis, an 
important way to treat RF. However, hemodialysis in 
children involves some risks and even leads to death 
due to their inappropriate arteries and presence of 
abdominal tumors or severe thrombocytopenia. Thus, 
the best way to deal with this problem is prevention 
including four main matters. The first one is proper 
hydration to increase urine volume. Secondly, the 
administration of sodium bicarbonate should be done to 
maintain urine PH>7 in order to enhance the solubility 
of uric acid 
[12]
. Thirdly, to decrease the serum uric acid 
level, the agents like rasburicase and allopurinol must 
be used 
[13]
 and finally taking drugs that increase serum 
urate or acidify urine such as thiazides or salicylates 
should be avoided 
[14]
. 
In conclusion, according to our cases, it is 
important to pay attention to mediastinal mass in CXR 
when we face to a patient with ARF related to tumor 
lysis syndrome. 
 
Table 1. Cario-Bishop definition of laboratory tumor lysis syndrome and clinical tumor lysis syndrome 
Laboratory Tumor lysis syndrome 
Metabolite or electrolyte criterion for diagnosis 
Uric acid ≥8mg/dL or 25% increase from baseline 
Potassium ≥6meq/L or 25% increase from baseline 
Phosphorus ≥6.5 mg/dL (children) ,≥4.5 mg/dL (adult) or 25% increase from baseline 
Calcium ≥25% increase from baseline 
Clinical tumor lysis syndrome: 
LTLS* and one or more of the following: 1) creatinine × ≥1.5 ULN* (age>12 years of age or age adjusted) 
2) cardiac arrhythmia or sudden death 3) seizure 
* LTLS: Laboratory tumor lysis syndrome, ULN: Upper limit of normal 
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